Paradigm Biocapital Advisors’s Ascendis Pharma A/S ASND Stock Holding History

Paradigm Biocapital Advisors’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-664,307	Closed	-$90.6M	–	36
2024 Q2	$90.6M	Buy	664,307 +156,355	+31%	+$21.3M	3.47%	11
2024 Q1	$76.8M	Buy	507,952 +156,252	+44%	+$22.3M	2.7%	19
2023 Q4	$44.3M	Buy	+351,700	New	+$35.1M	2.07%	17
2023 Q2	–	Sell	-350,866	Closed	-$37.6M	–	31
2023 Q1	$37.6M	Sell	350,866 -1,942	-0.6%	-$222K	3.57%	16
2022 Q4	$43.1M	Sell	352,808 -144,539	-29%	-$16.8M	5.06%	9
2022 Q3	$51.4M	Buy	497,347 +65,177	+15%	+$6.18M	6.85%	4
2022 Q2	$40.2M	Buy	432,170 +110,549	+34%	+$10.4M	8.01%	6
2022 Q1	$37.7M	Buy	321,621 +103,463	+47%	+$12M	9.98%	1
2021 Q4	$29.3M	Buy	+218,158	New	+$32.5M	8.38%	2

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Paradigm Biocapital Advisors's ASND Position: Q3 2024 in Review

Paradigm Biocapital Advisors sold out of Ascendis Pharma A/S (ASND) in Q3 2024, closing a stake of 664,307 shares — an estimated $90.6M sold.

Paradigm Biocapital Advisors first reported a position in ASND in Q4 2021 and held it in 9 quarters. The position peaked at $90.6M in Q2 2024. 219 funds tracked by Wall St. Rank hold ASND as of Q3 2024.

Paradigm Biocapital Advisors reported no remaining Ascendis Pharma A/S position as of Q3 2024 after selling out during the quarter.
Paradigm Biocapital Advisors sold 664,307 Ascendis Pharma A/S shares in Q3 2024, an estimated $90.6M.
Paradigm Biocapital Advisors first reported a position in Ascendis Pharma A/S in Q4 2021 and held it in 9 quarters.
Paradigm Biocapital Advisors's Ascendis Pharma A/S position peaked at $90.6M in Q2 2024.
219 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2024.

Based on Paradigm Biocapital Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.